90 related articles for article (PubMed ID: 2478510)
1. Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer.
Landmann C; Hunig R
Int J Radiat Oncol Biol Phys; 1989 Nov; 17(5):1073-6. PubMed ID: 2478510
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer.
Ritter MA; Messing EM; Shanahan TG; Potts S; Chappell RJ; Kinsella TJ
J Clin Oncol; 1992 Aug; 10(8):1208-17. PubMed ID: 1378886
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen in the follow-up of prostatic adenocarcinoma treated with external beam radiation.
Kellokumpu-Lehtinen P; Nurmi M; Koskinen P; Irjala K
Urol Int; 1991; 46(1):6-8. PubMed ID: 1708923
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker.
Dundas GS; Porter AT; Venner PM
Cancer; 1990 Jul; 66(1):45-8. PubMed ID: 1693877
[TBL] [Abstract][Full Text] [Related]
5. Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy.
Fijuth J; Chauvet B; Vincent P; Félix-Faure C; Reboul F
Radiother Oncol; 1992 Apr; 23(4):236-40. PubMed ID: 1376935
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen and external beam radiation therapy in prostate cancer.
Zagars GK; Sherman NE; Babaian RJ
Cancer; 1991 Jan; 67(2):412-20. PubMed ID: 1702349
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
Chauvet B; Félix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
[TBL] [Abstract][Full Text] [Related]
8. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate.
Schellhammer PF; Schlossberg SM; el-Mahdi AM; Wright GL; Brassil DN
J Urol; 1991 May; 145(5):1008-10; discussion 1010-1. PubMed ID: 1707987
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E
N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
12. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy.
Zagars GK
Int J Radiat Oncol Biol Phys; 1992; 23(1):47-53. PubMed ID: 1374065
[TBL] [Abstract][Full Text] [Related]
14. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy.
Russell KJ; Dunatov C; Hafermann MD; Griffeth JT; Polissar L; Pelton J; Cole SB; Taylor EW; Wiens LW; Koh WJ
J Urol; 1991 Oct; 146(4):1046-52. PubMed ID: 1716696
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen (PSA) and radiotherapy in locally confined prostate cancer.
Schaefer U; Micke O; Willich N
Anticancer Res; 1999; 19(4A):2645-8. PubMed ID: 10470211
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen levels during and after external beam radiotherapy for localized carcinoma of the prostate: predictor of therapeutic efficacy.
Rodrigus P; van Landeghem AA
Strahlenther Onkol; 1992 Jul; 168(7):397-401. PubMed ID: 1379747
[TBL] [Abstract][Full Text] [Related]
17. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.
Kavadi VS; Zagars GK; Pollack A
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):279-87. PubMed ID: 7523340
[TBL] [Abstract][Full Text] [Related]
18. [Prostatic specific antigen for detection and monitoring of prostatic cancer].
Gofrit O; Pode D; Gez E; Pfau A; Roizman I; Lifshitz Y; Barak V
Harefuah; 1992 Mar; 122(6):345-8, 408. PubMed ID: 1374729
[TBL] [Abstract][Full Text] [Related]
19. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
20. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection.
Magri V; Trinchieri A; Montanari E; Del Nero A; Mangiarotti B; Zirpoli P; de Eguileor M; Marras E; Ceriani I; Vral A; Perletti G
Arch Ital Urol Androl; 2007 Jun; 79(2):84-92. PubMed ID: 17695414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
